What is RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS used for?

( ARTG ) INDICATIONS AS AT 9 February 2004: Rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. Therapeutic drug monitoring of sirolimus is required.

What are the side effects of RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS?

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Does RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS interact with other medications?

Sirolimus is metabolized by theCYP3A4enzyme and is a substrate of theP-glycoprotein(P-gp)efflux pump; hence, inhibitors of either protein may increase sirolimus concentrations inblood plasma, whereas inducers of CYP3A4 and P-gp may decrease sirolimus concentrations in blood plasma.

Can RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS be used during pregnancy?

( AHT ) For the active ingredient sirolimus You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS — Description, Dosage, Side Effects | PillsCard

USDailyMed:Sirolimus AU:C L04AH01(WHO)L01EG04(WHO),S01XA23(WHO),QC01EB90(WHO) US:℞-onlyEU:Rx-only (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-2-propanyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone 53123–88–9Y 5284616 DB00877Y 10482078Y W36ZG6FT64 D00753Y CHEBI:9168Y ChEMBL413Y RAP (PDBe,RCSB PDB) DTXSID5023582 Interactive image O[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4 InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14‍‍‍‍‍‍‍-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1YKey:QFJCIRLUMZQUOT-HPLJOQBZSA-NY Sirolimus, also known asrapamycinand sold under the brand nameRapamuneamong others, is amacrolidecompound that is used to coatcoronary stents, preventorgan transplant rejection, treat a rare lung disease calledlymphangioleiomyomatosis, and treatperivascular epithelioid cell tumour(PEComa).It hasimmunosuppressantfunctions in humans and is especially useful in preventing the rejection ofkidneytransplants. It is amammalian target of rapamycin(mTOR) kinase inhibitorthat reduces the sensitivity ofT cellsandB cellstointerleukin-2(IL-2), inhibiting their activity. This compound also has a use in cardiovasculardrug-eluting stenttechnologies to inhibitrestenosis. It is produced by thebacteriumStreptomyces hygroscopicusand was isolated for the first time in 1972, from samples ofS. hygroscopicusfound onEaster Island.The compound was originally named rapamycin after the native name of the island, Rapa Nui.Sirolimus was initially developed as anantifungalagent. However, this use was abandoned when it was discovered to have potent immunosuppressive andantiproliferativeproperties due to itsability to inhibit mTOR. It was approved by the USFood and Drug Administration(FDA) in 1999.Hyftor (sirolimus gel) was authorized for topical treatment of facialangiofibromain the European Union in May 2023.

RAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOS

User Reviews